Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-26
2008-09-23
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S323000, C544S325000
Reexamination Certificate
active
07427628
ABSTRACT:
Disclosed are compounds which bind α4integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 7026328 (2006-04-01), Konradi et al.
patent: 7135477 (2006-11-01), Konradi et al.
Tarkowski et al. Int. Arch. Allergy Immunol. 121(1) 25-33, 2000.
Grayson et al., J. Exp. Med., 188(11), 2187-2191, 1998.
Tiley et al., Drugs of the Future, 26(10), 985-998, 2001.
Konradi Andrei W.
Pleiss Michael A.
Semko Christopher M.
Smith Jenifer
Stappenbeck Frank
Balasubram Venkataraman
Elan Pharmaceuticals Inc.
LandOfFree
Heterocyclic compounds which inhibit leukocyte adhesion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds which inhibit leukocyte adhesion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds which inhibit leukocyte adhesion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3980690